An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
Price : $35 *
At a glance
- Drugs GSK 2647544 (Primary) ; GSK 2647544 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 29 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
- 20 Dec 2013 Planned end date changed from 1 Sep 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
- 21 Aug 2013 New trial record